Charlot Biosciences cellPhoresis™

Founded in 2016 by Dr. David Charlot, Charlot Biosciences (often referenced as CBio) is a pioneering biotechnology firm focused on non-destructive cell analysis. The company’s flagship technology, cellPhoresis™, utilizes microfluidics and electric fields to separate and analyze live cells based on their unique dielectric signatures. This innovation addresses the '14-day bottleneck' in vaccine and therapy manufacturing by providing rapid sterility and quality control results in under 24 hours without killing the samples.

Headquartered in Tampa, Florida, the brand is a product of academic and industrial collaboration, drawing from research conducted at institutions like Arizona State University and UC Irvine. The company has secured significant non-dilutive funding from organizations such as the Department of Defense (DOD) and the Coalition for Epidemic Preparedness Innovations (CEPI) to refine its portable, point-of-care-ready systems. As a minority-owned enterprise, Charlot Biosciences remains an independent entity dedicated to advancing biopharmaceutical manufacturing and pathogen detection through label-free cellular observation.